The IPO Buzz: Iambic Therapeutics (IAM Proposed) Launches $150 Million IPO
Iambic Therapeutics (IAM Proposed), a biotech targeting breast cancer and lung cancer, unveiled the terms for its $150 million IPO early today and launched the deal for pricing next week. The company is offering 9.38 million shares at a price range of $15.00 to $17.00 to raise $150 million, if priced at the $16.00 mid-point […]
October 8, 2026 Read More